Octavus Consulting- Evidence-Based Consulting Services.

Call us: +91 87500 88882

Email us: bd@octavusconsulting.com

Contact Us
Contact Us

Blog Standard

16
Feb
No Comments

Q2W Newsletter: Feb’26 Part 1

Key Outcomes: Venglustat delivered a pivotal P3 win in GD3 with strong neurological benefit and global filing plans, while Fabry development is uncertain after PERIDOT missed its primary endpoint FDA activity was strong, with Optune Pax approved as a long‑awaited new option in locally advanced pancreatic cancer and oveporexton granted priority review as a potential […]
Continue Reading
30
Jan
No Comments

Q2W Newsletter: Jan’26 Part 2

Key Outcomes: Ophthalmology expansion: Eylea 8 mg gained EU approval for macular edema following RVO, demonstrating comparable efficacy to 2 mg with longer dosing intervals, reinforcing the Bayer–Regeneron retina franchise Oncology advancements: Multiple KRAS-targeted programs progressed, with D3 Bio securing dual FDA INDs (G12D, G12C), and first patient dosing achieved by PAQ Therapeutics and Argo […]
Continue Reading
15
Jan
No Comments

Q2W Newsletter: Jan’26 Part 1

Key Outcomes: Daiichi initiated P3 of Datopotamab deruxtecan (Datroway) for NSCLC, Pfizer’s P3 BREAKWATER study showed promising combinations in BRAF V600E mCRC, reinforcing global ADC and targeted therapy focus Biopharma deal-making remained strong across oncology and immunology, with multiple high-value licensing and collaboration agreements Pipeline momentum was robust in neurology and rare diseases, as Eisai/Biogen […]
Continue Reading
15
Dec
No Comments

Animal Health 2025 | Market Trends & Innovations Explained – Octavus Insights Corner

Insights Details Month: Oct 25 Tags: Animal Health, Conference, Pre-clinical, Phase 1, Phase 2, Phase 3, US FDA, Europe, Company Profile, Product profile, Deal Analysis, Funding Analysis, Landscape, Livestock Animals, Companion Animals, Top Diseases, Grooming & Smart Health Monitoring Device, Economic Impact, Emerging Technology, Artificial Intelligence, Digital Technology, Policy, USA, Veterinary Clinical Trials, Global Market […]
Continue Reading

Subscribe Newsletter

Sign up to receive notifications about the latest news and events from us!